Data / Form D filings / Actym Therapeutics, Inc.
Actym Therapeutics, Inc.: Form D filings
Actym Therapeutics, Inc., a biotechnology company in Berkeley, CA, filed 2 Form D notices with the SEC between 2020 and 2023. The latest, on July 6, 2023, reports $11.2 million sold of a $27.5 million offering to 5 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 626 BANCROFT WAY, SUITE A, Berkeley, CA, 94710
- Phone
- (510) 256-7167
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1808722
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 6, 2023 | New notice | $27,539,376 | $11,238,333 | $16,301,043 | 5 | Jun 28, 2023 | sec.gov |
| Apr 9, 2020 | New notice | $41,194,276 | $14,106,048 | $27,088,228 | 28 | Mar 27, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christopher D Thanos | Executive Officer, Director | |
| Benjamin D Chen | Director | |
| Ron D Mazumder | Director | |
| Julie D Cherrington | Director | |
| Kanad D Das | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jul 3, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Actym Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.